Lilly(US:LLY) Hua Er Jie Jian Wen·2025-11-06 13:58Core Insights - Eli Lilly is strengthening its position in the weight loss drug market through new drug development and policy collaboration [1][3] - The experimental weight loss drug eloralintide has shown promising results, with patients losing an average of 20.1% of their body weight in mid-stage trials [2] - A potential pricing agreement with the White House could expand coverage for GLP-1 weight loss drugs under Medicare and Medicaid, benefiting Eli Lilly [1][3] Group 1: Drug Development - Eli Lilly's eloralintide, a new weight loss drug, demonstrated a 20.1% weight reduction in patients receiving the highest dose over 48 weeks [2] - The study included 263 overweight adults with at least one obesity-related complication, excluding type 2 diabetes [2] - The drug also showed improvements in waist circumference, blood pressure, lipid levels, blood sugar control, and inflammation markers [2] Group 2: Market Position and Pricing Strategy - Eli Lilly and Novo Nordisk are negotiating with the White House to lower the prices of their GLP-1 weight loss drugs in exchange for broader insurance coverage [1][3] - The pricing framework could favor Eli Lilly, as analysts believe it may catalyze growth by increasing drug accessibility for up to 15 million Americans [3][4] - Eli Lilly's Zepbound is rapidly gaining market share against Novo Nordisk's Wegovy, both priced over $1,000 per month but offering a $499 option for self-pay patients [3] Group 3: Future Prospects - Eli Lilly is also developing an oral version of its GLP-1 drug, Orforglipron, which is expected to be submitted for regulatory approval by the end of 2025 [5] - The competition for oral formulations is intensifying, with both Eli Lilly and Novo Nordisk aiming to launch their oral GLP-1 drugs soon [5] - The market for GLP-1 weight loss drugs is undergoing significant changes, with pricing and direct-to-consumer channels becoming central to the healthcare distribution model in the U.S. [5]